Erschienen in:
25.07.2020 | ASO Author Reflections
ASO Author Reflections: Discharge Without Opioids After Lumpectomy with Sentinel Node Biopsy Should be the Norm, Not the Exception
verfasst von:
Tracy-Ann Moo, MD, Monica Morrow, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
The opioid crisis has led to efforts to curb opioid over-prescription in the postoperative setting. Institutional and society guidelines on the number of opioid tablets that should be prescribed after various procedures have been developed,
1,
2 with 0–10 tablets recommended for lumpectomy with sentinel node biopsy (SLNB). Although some surgeons have stopped prescribing opioids after lumpectomy, a recent survey by the American Society of Breast Surgeons (ASBrS) showed that 80% still routinely prescribe opioids.
2 These figures indicate that despite an increased awareness of the adverse effects of prescription opioids, there are still barriers to adopting non-opioid discharge protocols. This may be due to the paucity of literature demonstrating feasibility and outcomes of discharge without opioids after lumpectomy/SLNB. There is also concern that a switch to discharge without opioids could result in poorly controlled postoperative pain, leading to subsequent patient calls and opioid prescription after discharge. Our study was designed to examine these concerns.
3 …